CP.TO 0.88VRT 8.93NVDA -0.07TSM 5.21JPM 2.67ZST.TO 0.01HSAV.TO -0.1HSUV.U.TO 0.01
Abbott Labs (ABT)

NYSE:ABT

Abbott Labs (ABT)

101.95
-1.41 (1.36%)
as of Sep 11, 2026, 8:00:00 pm Market Open.
355 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 12, 2026, 12:00 am

This summary was created by AI, based on 13 opinions in the last 12 months.

Abbott Labs (ABT) has faced significant challenges over the past year, marked by declining stock performance and reduced growth expectations. While its recent acquisition aimed at expanding its cancer treatment portfolio is viewed positively, it is anticipated to take time before it becomes accretive to earnings. Analysts note that although growth has slowed and market share has been lost, the company's diagnostics and devices business shows signs of potential recovery. Despite these hurdles, many experts still consider ABT a high-quality name in the healthcare sector, highlighting its reasonable valuation compared to historic PE ratios and consistent dividend history. Overall, while caution is advised due to technical weaknesses and elevated competition, there remains an underlying belief in the stock's long-term viability.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
ALC,ABT
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Abbott Labs(ABT)

Jun 14, 2022
(A Top Pick May 31/22, Down 10.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ABT has triggered its stop at $105. To remain disciplined we recommend covering the position at this time. This will result in a net investment loss of 12%, when combined with previous buy recommendations.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$102.52

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

It's a Monthly Gems opinion which is available only for Stockchase Premium

Curated by Allan Tong since 2019.
99+ opinions with 4.15 rating.

TOP PICK

Abbott Labs(ABT)

Jun 09, 2022

Abbott has handily beaten its last four quarters, pays a steady 1.61% dividend and trades at 27x. That valuation is a little higher than AbbVie's 21.34x and Johnson & Johnson's 24x though well below Eli Lilly's 46x. Stockchaser Mike O'Reilly trusts Abbott's management, performance and prospects.

Photo of The Monthly Gems by Allan TongThe Monthly Gems by Allan TongUnlock Rating
$112.71

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Abbott Labs(ABT)

May 31, 2022
Stockchase Research Editor: Michael O'Reilly ABT was embroiled in a whistleblower complaint that led to shutdown of a key baby formula plant. Now that the company has effectively been cleared of wrongdoing, the plant will be reopening and we again reiterate ABT as a TOP PICK. Recently reported earnings beat expectations and support at ROE of 28%. The have aggressively bought back shares and are retiring debt early. They are a Dividend Aristocrat, raising dividends for 50 consecutive years. We continue to recommend a stop loss at $105, looking to achieve $143 -- upside potential over 20%. Yield 1.6% (Analysts’ price target is $140.17)
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$117.15

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Abbott Labs(ABT)

May 17, 2022
(A Top Pick May 18/21, Down 2%) A diversified healthcare company including diagnostics, nutrtiion, and generic drugs. They made many Covid testing kits, so they benefitted from the pandemic. Shares got hit as the pandemic waned. Still, they've made a lot of money, so they can use that cash flow to buy other companies. The medical devices business will ramp up as surgeries do. Last quarter, their infant formula controversy led them closing their plants; later, ABT was cleared of wrongdoing, so this business will ramp back up. They increase their dividend each year. Pays 2% yield now.
Photo of Christine PooleChristine Poole
Owned
Unlock Rating
$114.43

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Abbott Labs(ABT)

Apr 13, 2022
(A Top Pick Jun 08/21, Up 11%) Still likes. Now above his buy price of $110. Watch and wait for a pullback, as there will be volatility with diagnostics testing winding off.
Photo of Chris BlumasChris Blumas
Owned
Unlock Rating
$119.68

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Abbott Labs(ABT)

Apr 05, 2022
Stockchase Research Editor: Michael O'Reilly ABT has benefited from COVID-19 testing worldwide, is the second largest cardiologic technology company in the world, and is a large player in the continuous glucose monitoring market for diabetes. It trades at 30x earnings, compared to peers at 23x; however, forward earnings support a 23x valuation. It is a little expensive at over 5x book value. It pays a small dividend (that has been growing for 50 years consecutively), backed by a payout ratio under 50% of cash flow. Its most recent earnings beat expectations by 11% and support a strong 27% ROE. It has been building cash reserves while paying down debt. We would recommend setting a stop loss at $105, looking to achieve $143 -- 18% upside potential. Yield 1.59% (Analysts’ price target is $142.88)
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$120.81

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

Mar 15, 2022

Has owned this for years, but is buying at current prices. They make the Covid-testing kits, totalling $10 billion revenues. Demand here will likely soften. The stock price is flat over the year, despite those revenues, but at least the cash flow from the testing can lead to more products and acquisition. They forecast they can grow revenues around 9%. Attractive stock price now. Diagnostic and medical devices are good business. Pharmas are selling to emerging markets. Their glucose monitoring system is doing well. Their heart products are a new source of growth. Attractive PE. (Analysts’ price target is $139.72)

Photo of Christine PooleChristine Poole
Owned
Unlock Rating
$116.96

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
TRADE

Abbott Labs(ABT)

Mar 14, 2022
An excellent company, a leader in medical diagnostics but he is not sure about current positioning. He doesn't want exposure to infectious diseases diagnostics. Wait for the area to act better and interest rates to stabilize.
Photo of David FingoldDavid FingoldUnlock Rating
$115.52

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Feb 04, 2022
Likes it. They got a lot of money from BinoxNOX, but they get no credit from it, so they need to deploy that money somehow. Meanwhile, their glucose monitor is selling very well--that's the reason to own it.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$129.71

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Jan 18, 2022
Has owned this many years. It's sensitive to the Covid testing environment, like now during Omicron. So, it's has a nice run from this increasing demand. But the market always looks forward, so Abbott doesn't enjoy that testing rise. They report later this month. She is waiting for a slightly lower entry point. Nobody knows what will happen with Covid, but the pandemic has given them a nice cash cushion while medical devices and diagonistics divisions are doing well and will grow, she think around 8-12%. She likes this long term.
Photo of Christine PooleChristine Poole
Owned
Unlock Rating
$126.53

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Abbott Labs(ABT)

Jan 17, 2022
An advisor could help the caller decide whether to hold or sell some. He doesn't own either The devices made by Abbott show promise for the stock so there is upside. The pharmaceutical side is not of particular interest. These are relatively defensive stocks but market could gravitate to cyclicals.
Photo of David FingoldDavid FingoldUnlock Rating
$128.16

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Nov 05, 2021
A Covid play, but he expects America to still be using their Covid testing kits for a long while to come despite medical breakthroughs.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
Owned
Unlock Rating
$124.37

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Oct 15, 2021
They report Wednesday. They warned of an earnings shortfall. They created a fast Covid test--great news--but then Delta hit those test sales. He's long owned this. He likes their great medical devices.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
Owned
Unlock Rating
$117.49

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

Oct 13, 2021
Diversified. Generics to EMs, medical devices, diagnostics, nutritionals. Covid tests. Outlook cut in June, as demand for rapid tests dropped. Now we're seeing increases in rapid tests. Good growth in med devices and diabetic monitoring. More in the pipeline. Attractive value. Increases dividend every year. She'd buy it here. Yield is 1.53%. (Analysts’ price target is $129.74)
Photo of Christine PooleChristine Poole
Owned
Unlock Rating
$117.50

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
Showing 61 to 75 of 223 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

KMB -0.33$98.15
XLV -0.3$165.36
META 3.65$648.03
DAL 1.67$79.91
ORCL -2.66$150.28

Today's Top Picks

CP.TO 0.88$123.84
VRT 8.93$257.06
NVDA -0.07$218.29
TSM 5.21$433.24
JPM 2.67$356.23

Popular Articles

Latest Sell Signals

ORCL -2.66$150.28
ORCL -2.66$150.28
URI 0.04$989.12
BBD.B.TO -4.9$300.82
BN.TO 0.29$52.93

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Shannon Saccocia, CIO, Boston Private

Shannon Saccocia, CIO, Boston Private

Boston Private

Kevin Simpson

Kevin Simpson

Capital Wealth Planning

Greg Newman

Greg Newman

Scotia Wealth Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like